Gene Therapies Must Bridge Gap Between Short-, Long-Term Efficacy
Sponsors for the three marketed gene therapies discussed lessons learned about acceptance and uptake of cell and gene therapies.
You may also be interested in...
The partnership helps close the gap between Nkarta and Fate Therapeutics in terms of the breadth of their pipelines.
Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.
The next-generation DMD drug showed dramatic improvement on exon dystrophin and exon skipping, but small numbers and adverse events give pause.